Air Pollution Fuels Surge in Asthma, COPD, Allergy Drug Sales in India

• India's worsening air quality is directly linked to increased sales of respiratory drugs, with the market growing significantly.
• The respiratory therapy segment has seen an 8% compound annual growth rate over five years, reaching Rs 18,913 crore.
• Anti-asthma and COPD products dominate, accounting for 61% of sales and growing at a 10% CAGR, driven by long-term maintenance therapies.
• Cough and cold market, 24% of sales, remains strong due to seasonal factors and persistent pollution-linked symptoms in urban areas.
• Systemic antihistamines and nasal preparations show rapid growth, reflecting rising allergy prevalence linked to environmental triggers.

Why It Matters: Worsening air quality and urban lifestyles are driving a significant surge in respiratory drug sales across India.